权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Selective Uptake and Hydrolysis of Cholesteryl Ester by SR-BI

SR-BI 选择性摄取和水解胆固醇酯

基本信息

批准号：
9128733
负责人：
Daisy Sahoo
金额：
$ 38.5万
依托单位：
MEDICAL COLLEGE OF WISCONSIN
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-04-01 至 2019-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9128733
关键词：
Address Affect American Architecture Atherosclerosis Binding Biological Assay Cell membrane Cells Cholesterol Cholesterol Esters Complex Data Dimerization Excision Excretory function Genes HDL cholesteryl ester Health Heart Diseases High Density Lipoprotein Cholesterol High Density Lipoproteins Human Hydrolysis Knowledge Ligand Binding Ligands Lipids Liver Malignant Neoplasms Mediating Membrane Molecular Mus Mutagenesis Mutation Oranges Outcome Pathology Patients Plasma Prevention Process Property Relaxation Research Resolution Role SR-BI receptor Series Staging Structure Technology Testing Transmembrane Domain Viral atherogenesis base cardiovascular risk factor design flexibility hypercholesterolemia improved in vivo innovation killings monomer mutant novel novel therapeutics particle prevent receptor research study reverse cholesterol transport three dimensional structure uptake

项目摘要

DESCRIPTION (provided by applicant): The receptor-ligand complex of scavenger receptor class B type I (SR-BI) and HDL is responsible for cholesterol disposal from the body via reverse cholesterol transport (RCT) and is critical in the prevention of dysfunctional HDL formation and atherosclerosis. The long-term objective of our research is to understand the mechanisms that regulate SR-BI-mediated delivery of cholesteryl ester (CE) from HDL to the liver for excretion. This proposal consists of two primary objectives that will test the overall hypothesis that cholesterol flux via RCT is dependent on the engagement of "functional" HDL particles with an oligomeric assembly of highly- structured SR-BI. Aim 1 is designed to determine the oligomeric organization of the transmembrane (TM) domains of SR-BI and their role in facilitating the selective uptake of HDL-CE. First, we will use cutting-edge NMR strategies to determine the high-resolution structures and dimerization properties of the TM domains of SR-BI. Next, we will design structure-guided mutants of SR-BI to define the requirement of ligand-induced changes in proximity and orientation of the TM domains of SR-BI in the selective uptake of HDL-CE. Together, these studies will test the hypothesis that the structural organization and conformational flexibility of the TM domains of SR-BI are critical in mediating the selective uptake of HDL-CE into the plasma membrane. In Aim 2, we will use a series of cell-based assays and in vivo experiments to determine the downstream consequences of an impaired HDL/SR-BI interaction. First, we will determine the mechanisms by which oxidatively-modified HDL prevents efficient selective uptake of HDL-CE. Second, we will determine whether SR-BI deficiency produces dysfunctional HDL particles in vivo. Finally, we will determine the effects of human mutants of SCARB1 (the human SR-BI gene) on RCT and atherosclerosis. This set of experiments will help us test the hypothesis that disruptive receptor/ligand interactions prevent HDL clearance via SR-BI-mediated selective uptake and RCT, and result in the formation of dysfunctional HDL particles that promote atherogenesis. Together, these studies will identify (i) the mechanisms by which HDL-induced conformational changes associated with the SR-BI oligomeric complex facilitate the selective uptake process and (ii) how impaired receptor/ligand interactions impede the selective uptake process and decrease RCT, resulting in the formation of dysfunctional, atherogenic HDL particles. We anticipate the findings from these studies will help identify novel therapeutic strategies for treating hypercholesterolemia and its associated pathologies such as atherosclerosis.